January 23, 2020
The first clinical trial data from 13 pancreatic cancer patients treated with LOAd703 and standard of care chemotherapy was presented at GI ASCO San Fransciso. The full study Arm 1 with 18 response evaluable patients will be presented late 2021/early 2022. Arm 2 combining LOAd703, chemotherapy and checkpoint inhibition has begun to enroll patients.
![]()
